MedPath
HSA Approval

ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML

SIN17059P

ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML

ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML

August 5, 2024

A. MENARINI SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantA. MENARINI SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01XX67

Manufacturer Information

A. MENARINI SINGAPORE PTE. LTD.

Alcami Carolinas Corporation

Active Ingredients

TAGRAXOFUSP

1.0 MG/mL

Tagraxofusp

Documents

Package Inserts

Elzonris Infusion PI.pdf

Approved: August 5, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ELZONRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1000 MCG/ML - HSA Approval | MedPath